A Randomised, Double-Blind, Placebo-Controlled Trial of Metformin on Myocardial Efficiency in Insulin-Resistant Chronic Heart Failure Patients without Diabetes
Anders Hostrup Larsen(Aarhus University), Henrik Wiggers(Aarhus University Hospital), Lars Poulsen Tolbod(Aarhus University Hospital), Jørgen Frøkiær(Canon (Japan)), Steen Hvitfeldt Poulsen(Amyloidosis Foundation), Flemming Nielsen(Odense University Hospital), Helene Nørrelund(Regionshospitalet Viborg), Jens Christian Hedemann Sørensen(Uppsala University), Niels Jessen(Steno Diabetes Centers), Søren Feddersen(Odense University Hospital), Nils Henrik Hansson(Aarhus University Hospital), Kim Brøsen(Odense University Hospital), Hendrik J. Harms(Amsterdam UMC Location VUmc)
Cited by 66
Related Papers
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|714
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
|European Journal of Heart Failure|2016|561
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
|Circulation|2019|513
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2024|453
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|356